Oxagen Limited

Asterand UK Limited

Pharmagene Laboratories Limited

Mark Richard Ashton

Edward Andrew Boyd

Frederick Arthur Brookfield

Mark Whittaker

Eric Roy Pettipher

David Middlemiss

Michael George Hunter

Chris Palmer

Alexander W Oxford

George Hynd

Jonathan Mark Sutton

David Edward Clark

Kenneth Lyle Clark

Garry Fenton

Robert Alexander Coleman

Richard Jon Davis

Neil Victor Harris

Shirley Ann Brunton

Keith Alfred James Stuttle

The present invention provides indole derivatives that antagonize prostaglandin D, and that can be used to treat inflammatory diseases mediated by prostaglandin D.

Treatment of CRTH2-mediated diseases and conditions

A compound of formula (III): or a salt, solvate and chemically protected form thereof, wherein: Ris an optionally substituted Caryl or Calkyl group; L' is a single bond, &#x2014;O&#x2014; or &#x2014;C(&#x2550;O)&#x2014;; A is selected from the group consisting of: formula (i) (ii) (iii) wherein X and Y are selected from the group consisting of: O and CR; S and CR; NH and CR; NH and N; O and N; S and N; N and S; and N and O, and where the dotted lines indicate a double bond in the appropriate location, and where Q is either N or CH; D is selected from: formula (i) (ii) (iii) (iv) (v) (vii) (viii) (ix) B is selected from the group consisting of: formula (A) (B) where Ris selected from fluoro and chloro; and Ris either: (i) &#x2014;COH; (ii) &#x2014;CONH; (iii) &#x2014;CH&#x2014;OH; or (iv) tetrazol-5-yl. 

[object Object]

The disclosure provides EPreceptor agonist compounds and methods for using the compounds for treating conditions which can be alleviated by agonism of an EPreceptor.

A compound of formula (I): or a salt, or chemically protected form thereof, wherein: Ris an optionally substituted phenyl;   Where Ris selected from H and Calkyl; where one of Rand Ris &#x2014;C-alkylene-Rand the other of Rand Ris H, m and n can be 0 or 1, and m+n=1 or 2; and additionally, when Ris &#x2014;C-alkylene-R, m can also be 2 or 3, and m+n=1, 2, 3 or 4, and when Ris tetrazol-5-yl, m+n may be 0; or where one of Rand Ris &#x2014;O&#x2014;CH&#x2014;R, and the other of Rand Ris H, n is 0; Ris H or optionally substituted Calkyl; Ris either: (i) &#x2014;COH; (ii) &#x2014;CONH; (iii) &#x2014;CH&#x2014;OH; or (iv) tetrazol-5-yl.

EP2 receptor agonists

Compounds for the treatment of CRTH2-mediated diseases and conditions

A compound of formula (I): or a salt, solvate and chemically protected form thereof, wherein: wherein X and Y are selected from the group consisting of:  

Growing community of inventors

Abingdon, United Kingdom

Mark Richard Ashton